Vivus VVUS

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Vivus Up On Erectile Dysfunction Drug - What Should Investors Expect?

      Headlines

      Fri, 19 Sep 2014

      By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced today that the company ..... hour or longer to bring results. Vivus stock soared as high as $4.82 during ..... there. As stated, the label gives Vivus a leg up on the competition in the

    2. It Takes Less Than 15 Minutes To Buy VVUS Shares!

      Headlines

      Fri, 19 Sep 2014

      International (NASDAQ: ENDP ). Vivus Pharmaceuticals (NASDAQ: VVUS ) shares have fallen dramatically ..... What is the revenue potential for VIVUS ? There has been, at times wild ..... Discussion of the earnings potential Vivus ' Complete Story »

    3. Alibaba: An Opportunity Or The Opportunity

      Headlines

      Fri, 19 Sep 2014

      By Nicholas Mushaike : What's really for Sale? Alibaba (Pending: BABA ) is listing as a Variable Interest Entity (VIE) - an entity necessary to get around China's strict foreign investment rules. This arrangement produces a complicated ownership structure that could mean major headaches for ...

    4. CORRECTED-UPDATE 1- Vivus' Stendra gets FDA approval for use 15 minutes before sex

      Headlines

      Thu, 18 Sep 2014

      (Corrects headline and first paragraph to make clear that Stendra was already approved for use 30 minutes before sex, and has now been approved for use as little as 15 minutes before sex)

    5. CORRECTED- Vivus' Stendra gets FDA approval for use 15 minutes before sex

      Headlines

      Thu, 18 Sep 2014

      (Corrects headline and first paragraph to make clear that Stendra was already approved for use 30 minutes before sex, and has now been approved for use as little as 15 minutes before sex)

    6. Midday Gainers / Losers

      Headlines

      Thu, 18 Sep 2014

      Top 10 Gainers: EMKR +26% . VVUS +15% . OTC:XXII +14% . VIMC +12% . ICCC +11% . RLJE +11% . BSPM +10% . OTC:SYRX +13% . ACLS +10% . PWE +10

    7. Premarket Gainers / Losers

      Headlines

      Thu, 18 Sep 2014

      Gainers: EMKR +39% . OTC:XXII +17% . VVUS +14% . ZGNX +9% . PWE +9% . Losers: MCHX -37% . RAD -13% . PIR -12% . VHC -8% . PDLI -7% . Post your comment!

    8. Vivus set for gap up at the open

      Headlines

      Thu, 18 Sep 2014

      Vivus (NASDAQ: VVUS ) is up 16% premarket on robust volume in response to the Stendra label expansion . Post your comment!

    9. FDA clears Stendra label expansion

      Headlines

      Thu, 18 Sep 2014

      The FDA approves a label expansion for Vivus ' (NASDAQ: VVUS ) erectile dysfunction (ED) drug Stendra ( avanafil ) that reduces the ..... 15-minute approval triggers a $15M milestone payment from Auxilium to Vivus . Post your comment!

    10. Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away

      Headlines

      Tue, 16 Sep 2014

      all took place before the FDA approval of Belviq and Qsymia from Arena Pharmaceuticals (NASDAQ: ARNA ) and Vivus Inc. (NASDAQ: VVUS ) respectively. There was a good reason for the FDA to be cautious to approve Contrave back in 2011, though

    « Prev12345Next »
    Content Partners